title: Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE.
abstract: OBJECTIVE
  Widespread screening for prostate cancer in the United States has resulted in earlier tumor identification at lower stages. The fewer number of men with lymph node metastases at initial presentation has altered patterns of pelvic lymphadenectomy before definitive treatment. We characterized patterns of pelvic lymphadenectomy in conjunction with radical prostatectomy in a community based cohort.
  
  
  METHODS
  In the CaPSURE database we identified men undergoing radical prostatectomy. Patients were stratified into 3 clinical risk groups based on serum prostate specific antigen, T stage and pathological grade. We examined temporal trends of pelvic lymphadenectomy and predictors of pelvic lymphadenectomy.
  
  
  RESULTS
  From 1992 to 2004 the proportion of men undergoing pelvic lymphadenectomy in conjunction with radical prostatectomy decreased from 94% to 80%. Overall positive lymph nodes were identified in 0.87%, 2.0% and 7.1% of men in the low, intermediate and high risk groups, respectively. While men with high risk disease continued to undergo pelvic lymphadenectomy at a high rate (greater than 90%), the fraction of men at low and intermediate risk undergoing pelvic lymphadenectomy steadily decreased. Prostate specific antigen, Gleason sum, clinical stage and income were factors associated with pelvic lymphadenectomy. A mean of 5.7 lymph nodes (median 5.0) were removed.
  
  
  CONCLUSIONS
  The performance of pelvic lymphadenectomy has decreased in patients at low and intermediate risk, and remained stable in patients at high risk. Further investigation of the role of extended pelvic lymphadenectomy and the potential therapeutic benefits of pelvic lymphadenectomy would better define the contemporary role of pelvic lymphadenectomy and identify appropriate candidates.
authors.affiliation: Urologic Outcomes Research Group, Program in Urologic Oncology, Department of Urology, University of California-San Francisco Comprehensive Cancer Center, University of California-San Francisco, California 94115-1711, USA.
authors.forename: Jun
authors.initials: J
authors.lastname: Kawakami
authors.forename: Maxwell V
authors.initials: MV
authors.lastname: Meng
authors.forename: Natalia
authors.initials: N
authors.lastname: Sadetsky
authors.forename: David M
authors.initials: DM
authors.lastname: Latini
authors.forename: Janeen
authors.initials: J
authors.lastname: Duchane
authors.forename: Peter R
authors.initials: PR
authors.lastname: Carroll
mesh_terms: D000368:Aged; D015331:Cohort Studies; D006801:Humans; D008197:Lymph Node Excision / Q000706:statistics & numerical data* / Q000639:trends*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010388:Pelvis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology* / Q000601:surgery*; D012042:Registries; D012189:Retrospective Studies
chemical_list: D017430:Prostate-Specific Antigen